CME-accredited Program

Stephen Harrison – Program Director

About the program

Nonalcoholic steatohepatitis (NASH) is the advanced, inflammatory subtype of non-alcoholic fatty liver disease (NAFLD) – the most prevalent liver disease in the western world.  NASH is characterized by a build up of fat in the liver leading to damage and inflammation, and increases the risk for progression to cirrhosis, liver failure, and hepatocellular carcinoma. 

Despite its implications, NASH is typically associated with non-specific symptoms, which can make it hard to diagnose in practice. There are additionally no current approved therapies for the indication, with the most common management strategy involving patient lifestyle changes.

This expert-led program aims to improve the diagnosis and management of NASH through education on pathophysiology, the mechanisms underlying disease progression, screening and diagnosis, current guidelines, and emerging therapies, using a real-life patient case study and virtual e-learning modules.

The site also includes an “Ask a question” hub, where you can share your questions directly with our esteemed faculty, and will be answered periodically.

Watch this brief introduction to the program by Stephen Harrison, Program Director

Learning objectives

Following completion of this independent educational program, you will be able to:

  • Understand NASH as a metabolic disease and the mechanisms underlying disease progression
  • Describe available non-invasive strategies for the diagnosis of NASH and identify patients at high risk for developing NASH
  • Discuss emergent therapies for the treatment of NASH and the clinical data behind them

Do you have a question for our panel of NASH experts? Why not share your thoughts or ask them a question using our form.

In this video module Quentin Anstee and Manal Abdelmalek will outline the common biomarkers for NASH, and discuss the current and future therapeutic landscape for the disease.

In this case study module, program director Stephen Harrison will describe the NASH patient journey, with reference to the disease course and management of a 65-year old NASH patient, including initial risk factors, diagnosis, management recommendations and emerging therapies in the field.

In this eLearning module, Vlad Ratziu will outline the pathophysiology of NASH, and its links to related comorbidities, as well as the progressive nature of the disease and the increased risk for patients to develop potential serious clinical outcomes.

Target audience

This independent educational program is suitable for hepatologists, primary care practioners and those in the multidisciplinary team worldwide who provide front-line care of patients with NAFL, and associated liver disorders.

Faculty

Program Director

Stephen Harrison

Visiting Professor of Hepatology Radcliffe Department of Medicine, University of Oxford, UK
Medical Director, Pinnacle Clinical Research, Texas, USA
President, Summit Clinical Research, Texas, USA

Dr Harrison earned his medical degree from the University of Mississippi School of Medicine.  He completed his internal medicine residency and gastroenterology fellowship at Brooke Army Medical Center and a 4th year advanced liver disease fellowship at Saint Louis University.  He is board certified in both Internal Medicine and Gastroenterology.

Dr Harrison is a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.  He is internationally known for studies in hepatitis C and non-alcoholic fatty liver disease with over 200 peer reviewed publications in these fields. Dr Harrison currently serves as the Medical Director for Pinnacle Clinical Research and the President of Summit Clinical Research in San Antonio, Texas.

Disclosures

Grants – Akero, Axcella, Cirius, CiVi, Cymabay, Enyo, Galectin, Galmed Research & Dev., Genfit, Gilead Sciences, Hepion, Hightide, Intercept, Madrigal, Metacrine, NGM, Northsea, Novartis, Novo Nordisk, Poxel Sagimet, Viking

Consulting – AgomAB, Akero, Alentis, Alimentiv, Altimmune, Axcella, Boston Pharma, B Riley, BVF Partners, Canfite, CiVi, Corcept, Cymabay, Echosens, Enyo, Fibronostics, Foresite, Fortress, Galectin, Genfit, Gilead, GNS, Hepion, Hightide, HistoIndex, Inipharm, Intercept, Ionis, Kowa, Madrigal, Metacrine, Microba, NGM, NorthSea, Novartis, Novo Nordisk, Nutrasource, Piper Sandler, Poxel, Prometic Pharma, Ridgeline, Sagimet, Sonic Incytes, Terns, Vikings

Funding

This activity is supported by an educational grant from NOVO NORDISK A/S.

Accreditation

In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) and Springer Healthcare IME.

NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NACCME designates AMA PRA Category 1 Credit™ for the following activities:

  • Completion of 15-minute patient case study: 0.25 AMA PRA Category 1 Credit™
  • Completion of 15-minute eLearning module: 0.25 AMA PRA Category 1 Credit™
  • Completion of 20-minute video module: 0.25 AMA PRA Category 1 Credit™
  • Completion of all components listed above and the opening/closing videos: 1.0 AMA PRA Category 1 Credit™

How to claim your credits

To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.

Planning Committee

In addition to the expert faculty, NACCME and Springer Healthcare IME planners and staff include Kristin Kolack, Rachel Goddard, James Hutton, and Alba Ruzafa. The Planning Committee have no financial relationships to disclose.

Contact us

[email protected]

Springer Healthcare IME
The Campus, 4 Crinan Street
London, N1 9XW, UK

Sign up for new content alerts

This activity is supported by an educational grant from NOVO NORDISK A/S.